Company Announcements

20230210_HORIZON THERAPEUTICS PLC_38.5 (b)_IE

Source: RNS
RNS Number : 7290P
Bank of America Merrill Lynch
13 February 2023
 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

BofA Securities, Inc.

Company dealt in

HORIZON THERAPEUTICS PLC

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - IE00BQPVQZ61

Date of dealing

10/02/2023

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

IE00BQPVQZ61


Long

Short

Number

%

Number

%

(1)

Relevant securities

358,128

0.157%

76,044

0.033 %

(2)

Derivatives (other than options):

307,381

0.134%

314,229

0.138%

(3)

Options and agreements to purchase/sell:

0

0%

37,600

0.016%

Total

665,509

0.291%

427,873

0.187%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

1

109.24 USD

Purchase

128

109.42 USD

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

   1,100

109.78 USD

Sale

      500

109.785 USD

Sale

      300

109.81 USD

Sale

      500

109.665 USD

Sale

 47,000

109.15 USD

Sale

       14

109.06 USD

Sale

      100

109.815 USD

Sale

      700

109.655 USD

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

Swaps

Increasing a Long Position

47,000

109.15 USD

Swaps

Increasing a Short Position

129

109.419 USD

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)




Collateral Delivery

Collateral Delivery of 167,500 shares

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

No

 

Date of disclosure

13/02/2023

Contact name

Frank Lui

Telephone number

+44207 996 6418

Name of offeree/offeror with which connected

AMGEN INC

Nature of connection (Note 9)

Advisor to - AMGEN INC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEFLFSIFIIVLIV